SS Innovations International Inc. (NASDAQ: SSII) announced record first-quarter 2026 financial results, with revenue surging 116.8% year over year to $11.1 million, underscoring the accelerating adoption of its SSi Mantra surgical robotic platform. The company's gross profit rose to $5.3 million from $1.1 million in the same period last year, reflecting higher system installations and increased procedure volumes. As of the quarter end, the installed base reached 194 SSi Mantra systems across 11 countries, with nearly 9,750 cumulative robotic procedures completed. This expansion is particularly significant for healthcare systems in emerging markets, where access to minimally invasive surgery has been limited.
The company's international reach grew substantially during the quarter, securing regulatory approvals in Sri Lanka, Kenya, Indonesia, and the Philippines. These approvals enable SS Innovations to penetrate new markets and address the growing demand for affordable surgical robotics in regions with underserved populations. The company continues to pursue regulatory clearance in both the United States and Europe, which could further expand its addressable market and establish the SSi Mantra as a competitive alternative to established robotic systems.
A landmark achievement during the quarter was the completion of the world's longest-distance robotic cardiac telesurgery, demonstrating the platform's remote surgery capabilities. This breakthrough has profound implications for healthcare delivery, potentially enabling specialist surgeons to perform procedures on patients in remote or underserved areas, reducing the need for patient travel and expanding access to expert care. The company's update as of June 22, 2026, noted that cumulative procedures reached 11,719, including 612 cardiac surgeries, 175 telesurgeries, and 212 pediatric surgeries. Additionally, approximately 2,100 physicians have been trained on the SSi Mantra, which has been utilized for over 170 different procedure types.
The strong financial performance and clinical milestones position SS Innovations as a key player in the surgical robotics space, particularly in emerging markets where cost-effective solutions are crucial. The company's ability to demonstrate clinical utility across multiple specialties and its innovative telesurgery platform could drive further adoption and potentially disrupt traditional models of surgical care. For more information, visit www.SSInnovations.com.
